Neurodegenerative disease refers to a range of partly inherited conditions that destroy the neurons in the human brain due to the progressive damage of the nerve cells caused by diseases.
Global Parkinson Disease Drug Biomarkers Insight 2028 Report Highlights:
- Global Parkinson’s Disease Antibodies Market Opportunity: > USD 8 Billion
- Parkinson’s Disease Clinical Trials Insight: > 300 Drugs In Trials
- Parkinson’s Disease Biomarkers Sourced During Clinical Trials
- Parkinson’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample:
http://biomarkersinsights.com/parkinson-disease-biomarkers-and-clinical-trials-insight-2028
Global Alzheimer’s Disease Drug Biomarkers Insight 2028 Report Highlights:
- Global Alzheimer’s Disease Antibodies Market Opportunity: > USD 5 Billion
- Alzheimer’s Disease Clinical Trials Insight: > 200 Drugs In Trials
- Alzheimer’s Disease Biomarkers Sourced During Clinical Trials
- Alzheimer’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample:
http://biomarkersinsights.com/alzheimers-disease-biomarkers-and-clinical-trials-insight-2028
Neurodegenerative disease refers to a range of partly inherited conditions that destroy the neurons in the human brain due to the progressive damage of the nerve cells caused by diseases. They are incurable diseases and patients with these diseases result in permanent loss of memory because of the degradation of neurons and inability of neurons to reproduce them. Parkinson disease and Alzheimer disease are the major neurodegenerative disorders which are profoundly occurred among the geriatric population above 60-65 years of age. Alzheimer disease is a progressive disorder that causes brain cells to degenerate and is the most common cause of dementia, a condition of progressive decline in thinking behavioral that disrupts a person ability to function independently. Similarly, Parkinson’s disease is a gradual progressive neurologic disease that results in slowing of voluntary movements, peculiar posture, and muscle weakness.
Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients’ life. However, in recent times the research is mainly focused on the development of novel targeted therapies which can target the underlying cause of the disease. Currently, more than 500 clinical trials are ongoing which are evaluating novel therapeutic approaches in the management of Parkinson diseases as well as Alzheimer disease. Several clinical pipeline drugs are expected to enter the market during the forecast period which will drive the growth of market. Apart from this, researchers are also focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.
The neurodegenerative disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of the global pharmaceutical firms are contributing to the dynamic nature of the market. They key players have also entered into collaboration to secure their position inn the market. For instance, Vyant Bio and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson disease. The collaboration brings together the respective teams’ expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential PD drugs. Further, Cognito Therapeutics and Aetion also announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment (MCI) and Alzheimer’s disease.
As per our report findings, the global Parkinson drug market is expected to surpass US$ 8 Billion whereas global Alzheimer drug market is expected to surpass US$ 5 Billion by 2028. Growing geriatric population and rising number of patients suffering from neurological disorders globally represent the key driving factors for the market growth. Further, rapid growth of the healthcare infrastructure, increase in medical researches, and strong product pipeline for neurodegenerative disease treatment are contributing significant share for boosting the market expansion. In addition, advancements in novel technology for the treatment and diagnosis of neurodegenerative diseases and rising research and development investment from major players are offering immense opportunities that can push the market expansion to a significant manner over the coming years.
Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. The study also provides insights into commercially available drugs for Parkinson disease and Alzheimer disease, and major drugs in research and development. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market’s future growth.
Contact:
Preeti Dureja
Research Partner
Biomarkers Insights
www.biomarkersinsights.com